• Cosopt contains dorzolamide (which is a sulfonamide) and, although administered topically, is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration, including severe skin reactions.

The following adverse events have occurred either at low incidence (<1%) during clinical trials or have been reported during the use of Cosopt in clinical practice where these events were reported voluntarily from a population of unknown size and frequency of occurrence cannot be determined precisely.